Skip to main content
BROOKS LABORATORIES LIMITED logo

BROOKS LABORATORIES LIMITED — Investor Relations & Filings

Ticker · BROOKS ISIN · INE650L01011 LEI · 984500FY0879C7971B73 BSE.NS Manufacturing
Open in API
Filings indexed 498 across all filing types
Latest filing 2022-11-23 Board/Management Inform…
Country IN India
Listing BSE.NS BROOKS

About BROOKS LABORATORIES LIMITED

https://www.brookslabs.net/

Brooks Laboratories Limited is a pharmaceutical manufacturing enterprise specializing in Contract Research and Manufacturing Services (CRAMS). The company focuses on the production of a diverse range of pharmaceutical formulations, including beta-lactam and non-beta-lactam products. Its portfolio encompasses various dosage forms such as dry powder injections, liquid injections, tablets, and capsules. Key therapeutic segments served include antibiotics, cardiovascular, gastrointestinal, and pain management. The company operates advanced manufacturing facilities designed to meet international quality standards, providing integrated solutions from formulation development to commercial-scale production. Brooks Laboratories emphasizes quality control and regulatory compliance to support its domestic and international client base.

Recent filings

Filing Released Lang Actions
Appointment
Board/Management Information Classification · 100% confidence The document is a formal announcement addressed to stock exchanges regarding the appointment of Ms. Jai Vaidya as the Company Secretary cum Compliance Officer. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including changes in management personnel. The content focuses solely on the appointment of a senior management official and includes details such as the effective date and brief profile. There is no financial data, report, or presentation included. Therefore, this document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2022-11-23 English
Newspaper Advertisements
Regulatory Filings
2022-11-16 English
Outcome of Board Meeting
Regulatory Filings
2022-11-14 English
Board Meeting — Financial results
Regulatory Filings
2022-11-05 English
General updates
Regulatory Filings Classification · 95% confidence The document is a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended 30th September 2022. It is a compliance certificate issued by the Registrar and Share Transfer Agent to the company and submitted to stock exchanges. The document is short (2693 characters) and serves as a regulatory compliance filing rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. It is primarily a regulatory compliance certificate related to securities dematerialisation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2022-10-13 English
Annual General Meeting
Regulatory Filings
2022-09-30 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.